Clinical Trial Update: Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer [NA]

View source ↗

Summary

A clinical study evaluating Rezvilutamide plus Docetaxel for abiraterone-resistant metastatic prostate cancer is currently enrolling by invitation at Zhujiang H…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Rezvilutamide (rezvilutamide)

Snippet

Sponsor: Zhujiang Hospital | Conditions: Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer | NA | Status: ENROLLING_BY_INVITATION